Gelteq (NASDAQ:GELS) Stock Price Up 1.9% – What’s Next?

Gelteq Limited (NASDAQ:GELS)’s stock price rose 1.9% on Thursday . The stock traded as high as $1.12 and last traded at $1.10. Approximately 48,232 shares were traded during trading, a decline of 98% from the average daily volume of 3,026,904 shares. The stock had previously closed at $1.08.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gelteq in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Gelteq Stock Up 1.9%

The firm’s fifty day moving average is $1.16 and its two-hundred day moving average is $1.48.

Institutional Investors Weigh In On Gelteq

A hedge fund recently bought a new stake in Gelteq stock. Susquehanna International Group LLP acquired a new position in Gelteq Limited (NASDAQ:GELS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.44% of Gelteq at the end of the most recent reporting period.

About Gelteq

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition.